Foghorn Therapeutics to Present at Hanson Wade's 5th Annual Targeted Protein Degradation Summit
October 20, 2022 07:00 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...
Foghorn Therapeutics to Participate in the Bank of America 2022 Precision Oncology Conference
September 27, 2022 08:00 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases...
Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
September 01, 2022 16:05 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases...
Foghorn Therapeutics Announces Change to Board of Directors
August 31, 2022 16:05 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases...
Foghorn Therapeutics Provides Further Update on FHD-286 Phase I Study in Relapsed/Refractory AML/MDS
August 23, 2022 07:00 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene...
Foghorn Therapeutics Appoints Lynne Parshall to its Board of Directors
August 17, 2022 07:00 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene...
Foghorn Therapeutics Provides Second Quarter 2022 Financial and Corporate Update
August 09, 2022 07:00 ET
|
Foghorn Therapeutics, Inc.
- FHD-286 dose escalation Phase 1 study in metastatic uveal melanoma continues to progress per protocol; working to resolve partial clinical hold in AML and MDS - On track to report initial...
Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
August 01, 2022 08:00 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically...
Foghorn Therapeutics Announces Upcoming Investor Conference Participation
May 31, 2022 16:05 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically...
Foghorn Therapeutics Provides Update on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML and MDS
May 19, 2022 16:01 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression...